Is lipoprotein-associated phospholipase A₂ correlated with cardiovascular risk in European women?
作者信息
Hirschler V
机构信息
Nutrition & Diabetes Department Hospital Durand, Buenos Aires, Argentina.
出版信息
Indian J Med Res. 2013 Dec;138(6):832-3.
Abstract
摘要
相似文献
1
Is lipoprotein-associated phospholipase A₂ correlated with cardiovascular risk in European women?脂蛋白相关磷脂酶A₂与欧洲女性的心血管风险相关吗？
Indian J Med Res. 2013 Dec;138(6):832-3.
2
Role of secretory phospholipase A₂ in women with metabolic syndrome.分泌型磷脂酶A₂在代谢综合征女性中的作用。
Indian J Med Res. 2013 Dec;138(6):866-72.
3
Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns study.年轻人的代谢综合征与颈动脉内膜中层厚度：载脂蛋白 B、载脂蛋白 A-I、C 反应蛋白和分泌型磷脂酶 A2 的作用：芬兰年轻人心血管风险研究。
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1861-6. doi: 10.1161/ATVBAHA.110.204669. Epub 2010 Jun 10.
4
Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives.炎症生物标志物与心血管风险评估。当前知识与未来展望。
Curr Pharm Des. 2013;19(21):3827-40. doi: 10.2174/13816128113199990307.
5
Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study.脂蛋白相关磷脂酶A2活性、铁蛋白水平、代谢综合征与10年心血管及非心血管死亡率：布伦内克研究结果
Eur Heart J. 2009 Jan;30(1):107-15. doi: 10.1093/eurheartj/ehn502. Epub 2008 Nov 19.
6
Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.分泌型磷脂酶 A2 对稳定型冠状动脉疾病患者的预后预测价值。
Clin Chem. 2011 Sep;57(9):1311-7. doi: 10.1373/clinchem.2011.166520. Epub 2011 Jul 22.
7
Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report.PCSK9 R46L变异携带者具有通过核磁共振光谱评估的抗动脉粥样硬化脂蛋白谱——简要报告。
Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):43-48. doi: 10.1161/ATVBAHA.116.307995. Epub 2016 Nov 17.
8
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.磷脂酶 A2 酶、大剂量阿托伐他汀与急性冠脉综合征后缺血事件预测。
Circulation. 2012 Feb 14;125(6):757-66. doi: 10.1161/CIRCULATIONAHA.111.063487. Epub 2012 Jan 9.
9
Novel insights of secretory phospholipase a(2) action in cardiology.分泌型磷脂酶a(2)在心脏病学中的新见解。
Trends Cardiovasc Med. 2009 Apr;19(3):100-3. doi: 10.1016/j.tcm.2009.06.003.
10
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.类风湿关节炎患者使用托珠单抗或阿达木单抗治疗后脂质及脂质相关心血管风险标志物变化的比较
Ann Rheum Dis. 2016 Oct;75(10):1806-12. doi: 10.1136/annrheumdis-2015-207872. Epub 2015 Nov 27.
本文引用的文献
1
Role of secretory phospholipase A₂ in women with metabolic syndrome.分泌型磷脂酶A₂在代谢综合征女性中的作用。
Indian J Med Res. 2013 Dec;138(6):866-72.
2
Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women.脂蛋白相关磷脂酶 A₂在多民族女性队列中对心血管疾病预测的临床实用性。
Clin Chem. 2012 Sep;58(9):1352-63. doi: 10.1373/clinchem.2012.188870. Epub 2012 Aug 2.
3
Lipid-related markers and cardiovascular disease prediction.脂质相关标志物与心血管疾病预测。
JAMA. 2012 Jun 20;307(23):2499-506. doi: 10.1001/jama.2012.6571.
4
Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature.脂蛋白相关磷脂酶 A2 在人口统计学特征和心血管危险因素中的变化：文献系统评价。
Atherosclerosis. 2012 Nov;225(1):11-21. doi: 10.1016/j.atherosclerosis.2012.06.020. Epub 2012 Jun 21.
5
Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study.脂蛋白相关磷脂酶 A(2)质量和活性与肥胖和糖尿病高发人群心血管疾病的风险：强心研究。
Diabetes Care. 2012 Apr;35(4):840-7. doi: 10.2337/dc11-1639. Epub 2012 Feb 14.
6
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.基于有效性的女性心血管疾病预防指南——2011年更新版：美国心脏协会指南
Circulation. 2011 Mar 22;123(11):1243-62. doi: 10.1161/CIR.0b013e31820faaf8. Epub 2011 Feb 14.
7
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.脂蛋白相关磷脂酶 A(2)与冠心病、卒中和死亡风险：32 项前瞻性研究的协作分析。
Lancet. 2010 May 1;375(9725):1536-44. doi: 10.1016/S0140-6736(10)60319-4.
8
Inflammation in atherosclerosis: from pathophysiology to practice.动脉粥样硬化中的炎症：从病理生理学到实践。
J Am Coll Cardiol. 2009 Dec 1;54(23):2129-38. doi: 10.1016/j.jacc.2009.09.009.
9
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.将脂蛋白相关磷脂酶A2检测纳入心血管疾病风险评估指南的共识小组建议。
Am J Cardiol. 2008 Jun 16;101(12A):51F-57F. doi: 10.1016/j.amjcard.2008.04.019.
10
Prevalence and cluster of cardiometabolic biomarkers in overweight and obese schoolchildren: results from a large survey in southwest Germany.德国西南部超重和肥胖学童中心血管代谢生物标志物的患病率及聚集情况：一项大型调查的结果
Clin Chem. 2008 Feb;54(2):317-25. doi: 10.1373/clinchem.2007.094821. Epub 2007 Dec 18.
Zotero 插件